In this study, we evaluated BluePrint standard and dual subtypes as a biomarker for predicting response to trastuzumab-containing neoadjuvant chemotherapy with or without pertuzumab in a large cohort of patients with HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.